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Abstract
Background: The aims of this study were to analyze associations of dopamine receptor genes (DRD1-5) with Major
Depressive Disorder (MDD) and nicotine dependence (ND), and to investigate whether ND moderates genetic influences on
MDD.
Methods: The sample was ascertained from the Finnish Twin Cohort. Twin pairs concordant for smoking history were
recruited along with their family members, as part of the multisite Nicotine Addiction Genetics consortium. Genetic
association analyses were based on 1428 adults. Total of 70 tagging single nucleotide polymorphisms within the dopamine
receptor genes were genotyped and analyzed for association with MDD, ND, and MD-ND co-morbidity. Individual level
logistic regression analyses were based on 1296 adults with data on ND and MDD diagnoses, as well as on dopamine
receptor genotypes adjusted for sex, age, and alcohol use. Four independent samples, such as population-based and case-
control samples, were used for replication.
Results: Rs2399496, located 1.5 kb downstream of DRD3, showed suggestive association for MDD (p= 0.00076) and
significant association for MDD-ND co-morbidity (p = 0.000079). Suggestive gene-(rs2399496) by-ND-interaction justified
analyses by genetic risk variant and ND status. Individuals with ND and two minor alleles (AA) of rs2399496 had almost six-
fold risk for MDD (OR 5.74, 95%CI 3.12–10.5, p = 9.010e-09) compared to individuals without ND and with two major alleles
(TT).
Conclusions: Significant association between a variant downstream of DRD3 and a co-morbid MDD-ND phenotype was
detected. Our results further suggest that nicotine dependence may potentiate the influence of the DRD3 genetic variant on
MDD.
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Introduction
Depression, ranging from mild depressed mood to major
depressive disorder (MDD) [1] is estimated to be the second
leading cause of disability worldwide by 2020 [2]. Approximately
8–13% of the general population experience clinical depression
during their lifetime [3]. Persistent smoking, being primarily
sustained by nicotine dependence (ND), represents one of the most
preventable causes of morbidity and mortality. Estimated preva-
lence of ND among Finnish ever smokers is 48–52% [4].
Depression is known to co-occur with smoking and ND [5].
While this association is well established, causal influences may be
posited under several hypotheses. Twin and family studies show
significant genetic correlations suggesting that shared genetic
predisposition underlies this co-occurrence [6]. Genes are
estimated to explain about 40% of variability in risk of developing
MDD [7], and 40–75% in etiology of ND [6]. Genome-wide
association (GWA) studies and meta-analyses show robust
association between the CHRNA5-CHRNA3-CHRNB4 nicotinic
acetylcholine receptor gene cluster on chromosome 15q25 and
smoking phenotypes including ND [8]. However, the identified
variants do not explain the extent of familial variation for ND.
Furthermore, although the CHRNA5-CHRNA3-CHRNB4 cluster
has been associated with many ND phenotypes, to our knowledge,
it has not been directly associated with MDD, although the
rs11636753 in CHRNB4 showed suggestive association with the co-
morbidity of MDD and ND [4].
Dopamine receptor genes may also be of interest to explain the
association between MDD and ND. Deficiency in dopaminergic
neurotransmission may underlie MDD symptomatology [2] and
dysfunctional mesolimbic dopamine system plausibly underlies
substance dependence [3]. Nicotinic acetylcholine receptors are
widely distributed in mesolimbic reward pathways. Thus, nicotine
can increase extracellular dopamine levels in these reward
pathways [2]. Candidate gene studies have implicated dopami-
nergic pathway genes in depression and ND. The role of DRD2
and ANKK1 variants in smoking and ND has been suggested in
various populations [9–13]. Variation in DRD2 has been
associated with depressiveness [14]. Evidence exists also for
involvement of DRD4 in mood disorders [15] and ND [16].
Genotype-by-phenotype-interactions concerning smoking and
depression have been sparsely investigated, with a few small-scale
studies focusing on dopamine receptor genes. A significant DRD4
genotype-by-depression-interaction was found for stimulation- and
negative-affect-reduction-smoking [17]. Likelihood of increased
smoking level rose 2-fold with each additional DRD2/ANKK1
rs1800497 minor allele, with a pronounced association among
adolescents with depression symptoms [18]. Further, the associ-
ation between smoking cessation and lifetime depression was
significantly modified by DRD2/ANKK1 rs1800497 genotype [19].
Given the co-occurrence and plausible shared etiology of ND and
depression, it is pertinent to investigate whether dopamine receptor
gene variants have pleiotropic associations on ND and MDD and
whether the association between dopamine receptor genes and ND is
modified by MDD - or vice versa.
We aimed to investigate: 1) magnitude of shared genetic factors
underlying the association between lifetime DSM-IV diagnoses of
MDD and ND; 2) whether ND moderates genetic influences on
MDD or vice versa; 3) dopamine receptor genes’ single nucleotide
polymorphisms (SNPs) for associations with MDD and ND.
Finally, we tested two alternative hypotheses: A) MDD modifies
the association between dopamine receptor genotype and ND; B)
ND modifies the association between dopamine receptor genotype
and MDD.
Methods
Ethics Statement
The authors assert that all procedures contributing to this work
comply with the ethical standards of the relevant national and
institutional committees on human experimentation and with the
Helsinki Declaration of 1975, as revised in 2008.
Sample
Sample collection has been previously described in detail
[20,21]. It was ascertained from the Finnish Twin Cohort of
adult twins born in 1938–1957. Based on earlier questionnaires,
ever-smoking concordant twin pairs and their family members
were recruited in 2001–2005 for the Nicotine Addiction Genetics
(NAG) Finland study, as part of the consortium including Finland,
Australia, and USA. Data from diagnostic interview, blood
samples, and informed consent were available on 2188 individuals.
The study was approved by the Ethics committee of the Hospital
District of Helsinki and Uusimaa, Finland and by the IRB of
Washington University, St. Louis, Missouri, USA.
The quantitative genetic models included 115 MZ and 415 DZ
pairs. The genetic association analyses included 1428 individuals
(1128 twins, 271 siblings, 29 other family members; mean age 55.6
years, 59% males) who smoked on average 19.7 (SD 9.9) cigarettes
per day (CPD). Ninety four percent had smoked $100 cigarettes
over lifetime, 51.5% fulfilling the ND DSM-IV criteria. Prevalence
of DSM-IV MDD was 17.2% (Table 1A). Multiple logistic
regression analyses included 1296 individuals (mean age 55.2
years, 60.6% males). All had smoked $100 cigarettes over lifetime
the average CPD being 18.9 (SD 10.4). ND and MDD prevalence
was 54.5% and 18.4%, respectively (Table 1B).
Phenotypes
Participants were interviewed using the diagnostic Semi-
Structured Assessment for the Genetics of Alcoholism (SSAGA)
[22] protocol including an additional section on smoking behavior
and ND adapted from the Composite International Diagnostic
Interview (CIDI) [23]. The following phenotypes were used:
DSM-IV diagnosis of lifetime MDD (presence of depressed mood,
irritable mood when age ,18 years or diminished interest or
pleasure in activities; altogether $5 symptoms out of 9 symptoms
of depression clustering within 2 weeks leading to impairment in
social, occupational or other important functioning), number of
DSM-IV MDD symptoms, DSM-IV diagnosis of ND ($3
symptoms out of 7, occurring within a year), number of DSM-
IV ND symptoms, and the binary phenotype of co-morbidity of
MDD and ND. (Phenotype correlations are presented in Table S1
in File S1). In hypothesis testing sex, age and alcohol use (defined
as number of binge drinking days per year, binge drinking
meaning $5 drinks at one occasion) were considered as potential
confounders. In post-hoc analyses heavy smoking ($20 CPD
during heaviest smoking period or $40 cigarettes in a single day)
was used.
Genotyping
DNA was extracted from blood samples by standard methods.
Altogether 303 individuals were genotyped for 76 SNPs in all
known dopamine receptor genes (DRD1-5) using Sequenom’s
homogeneous hME and iPLEX Gold technology (Sequenom, San
Diego, CA, USA), as previously described [4]. For 1125
individuals, genotypes were derived from GWA data. Of the 76
SNPs genotyped with Sequenom, 70 were available in the GWA
data (21 DRD1 SNPs, 30 DRD2/ANKK1 SNPs, 15 DRD3 SNPs,
two DRD4 SNPs, and two DRD5 SNPs). All analyses in this paper
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are based on these 70 SNPs. Genotyping was performed at the
Welcome Trust Sanger Institute (Hinxton, UK) on the Hu-
man670-QuadCustom Illumina BeadChip (Illumina, Inc., San
Diego, CA, USA), as previously described [4]. Altogether 29
markers were genotyped, 41 being imputed using IMPUTE v2.1.0
[24] using HapMap rel#24 CEU - NCBI Build 36 (dbSNP b126)
as reference panel. The reference panel used in the imputation was
HapMap rel#24 CEU - NCBI Build 36 (dbSNP b126). The
posterior probability threshold for "best-guess" imputed genotype
was 0.9: genotypes below the threshold were set to missing.
Marker quality controls are presented in Table S2 in File S1.
Statistical Analyses
Logistic Regressions. To verify the expected association
between lifetime MDD and ND, individual level logistic regres-
sions were applied for the affected/non-affected phenotypes
adjusted for sex, age, and alcohol use, using the Stata 11.1
statistical software 1 [25]. Since observations on members within
family may be correlated, this dependence (i.e. lack of statistical
independence of individual observations due to genetic and
familial factors) was statistically accounted for by using robust
estimators of variance and the cluster option when estimating
standard errors [26].
Quantitative Genetic Modeling. The quantitative genetic
models included 115 MZ and 415 DZ twin pairs. A bivariate
Cholesky decomposition for number of MDD and ND symptoms
was conducted to estimate the genetic and environmental
correlations underlying the phenotypic association. Univariate
moderation models were conducted to examine whether the
number of ND symptoms moderates the magnitude of genetic or
environmental variance of MDD symptoms, and vice versa. This
model extends the standard univariate twin model by adding a
moderator effect, b, on the estimated additive genetic, common
environmental and unique environmental paths of the model. A b
coefficient that differs significantly from zero is regarded as
evidence for a moderating effect on the genetic or environmental
path in question. The model takes into account the phenotypic
association between the two traits [27]. The modeling was
conducted with the statistical package Mx, using standard Mx
scripts (http://www.psy.vu.nl/mxbib/).
Linkage Disequilibrium Analyses. The linkage disequilib-
rium (LD) between SNPs was estimated among non-related
individuals (one per family) by using Haploview 4.2 [28].
Haplotype blocks were defined according to the ’solid spine of
LD’ algorithm by using the default threshold values for block
estimation.
Genetic Association Analyses. Qualitative association anal-
yses were performed with Pseudomarker [29], which performs
separate and joint linkage and LD analyses, testing each marker
locus against a phenotype-based ’pseudomarker’ locus. This
likelihood-based estimation method is numerically equivalent to
model-free analysis, and efficiently uses data on all family types.
Both recessive and dominant models (default parameters) were
fitted. Additive model could not be tested as it is not implemented
in Pseudomarker. P-values were minimized over ’LD given
linkage’, ’LD given no linkage’, and ’LD and linkage’ (joint test),
as well as dominant and recessive models. Quantitative association
analysis was performed with QTDT [30] with sex and age at
recruitment as covariates. In the analysis the proportion of alleles
shared identically by descent (IBD) were estimated by multipoint
computation of MERLIN [31] to extract maximal inheritance
information from the pedigrees. The total association model was
used, allowing powerful analysis of the sample including incom-
plete families. In the analysis, the variance components ’polygen-
ic’, ’non-shared environment’ (environmental effects unique to
each family member), ’common environment’ (environmental
effects shared by all related individuals), ’nuclear family environ-
ment’ (environmental effects shared by all members of a nuclear
family), and ’twin environment’ (environmental effects shared only
by twins) were used to model the phenotypic similarities between
related individuals.
Hypothesis Testing. For testing the study hypotheses, we
conducted logistic regressions to analyze the effect size and
significance of rs2399496 coded 0 (TT = 0 minor alleles), 1
(TA = one minor allele), and 2 (AA = two minor alleles). We used
the recessive model as the previous genetic association analyses
produced the best results on this gene when using a recessive
model. When testing the hypothesis (A) ‘Genetic vulnerability
potentiated by self-medication’ the outcome was binary ND, while
the assumed modifying variable was MDD. Gene-by-MDD-
interaction was tested using the Nested Likelihood-ratio approach.
When testing the hypothesis (B) ‘Genetic vulnerability potentiated
by chronic exposure to risk factor’ the outcome was binary MDD,
while the assumed modifying variable was ND. Similarly, gene-by-
ND-interaction was tested using the Nested Likelihood-ratio
approach. Logistic regression analyses were adjusted for sex, age,
and alcohol use and clustering by family number option was
applied [26].
Accounting for Multiple Testing. To account for multiple
testing we used a modified Bonferroni correction to set p-value
thresholds for significant and suggestive association. As the
analyzed markers and traits are correlated, the number of
independent markers and traits was estimated with SNPSpD
and matSpD [32], respectively, and their MeffLi and VeffLi
estimates [33] were used as they were smaller than Meff and Veff,
respectively, as recommended by the author (http://gump.qimr.
edu.au/general/daleN/SNPSpD/). In our data set, the number of
independent markers was 36.9, and the number of independent
traits was 3.20. A p-value threshold of 0.00042 for significant
association was achieved by dividing p = 0.05 by the product of the
number of independent markers and the number of independent
traits. A p-value threshold of 0.0014 for suggestive association was
achieved by dividing p = 0.05 by the number of independent
markers.
Replication
In an attempt to replicate the detected association, we analyzed
the top-three SNPs (rs2399496, rs3732790, and rs2134655) in four
independent data sets as follows: a Finnish adolescent twin sample
[FT12: N = 967, DSM-IV MDD and Fagerstro¨m Nicotine
Dependence Test (FTND) available], a Finnish adult population
sample of unrelated individuals [Health2000: N = 2123, CIDI for
major depressive episode, Beck Depression Inventory (BDI),
smoking status, and CPD available], an Australian twin family
sample (NAG-OZALC: N = 4425, DSM-IV MDD and DSM-IV
ND available], and a Dutch sample combining data of the
Netherlands Twin Register (NTR) and Study of Depression and
Anxiety (NESDA) studies (NTR-NESDA: N = 1613 MDD cases,
N = 1661 controls, DSM-IV MDD, FTND, and ever smoking
available). These replication datasets are described in detail earlier
[34–39].
In two of the replication samples, FT12 and the Health2000,
the analyses were performed respectively with the study sample. In
the NAG-AUS replication sample analyses were performed using
MQLS (http://www.sph.umich.edu/csg/liang/MQLS/) [40] for
the binary traits and MERLIN (http://www.sph.umich.edu/csg/
abecasis/Merlin/index.html) [31] or MERLIN Offline for the
continuous variables. Finally, in the Dutch NTR-NESDA
Nicotine Dependence, DRD3 and Depression
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replication sample analyses were performed using PLINK (http://
pngu.mgh.harvard.edu/purcell/plink/) [41] logistic regression
adjusting for age, sex, and principal components to correct for
population stratification. The SNP associations with MDD were
first tested in the whole sample, and then restricted to ever
smokers. Next, SNP associations with ND were tested among
smokers with data on FTND (cases defined as FTND$4, controls
defined as FTND 0–3). Finally, SNP associations with MDD-ND
co-morbidity were tested among smokers with data on FTND.
Genotype data for three SNPs in DRD3 (rs2399496, rs3732790,
and rs2134655, or correlates of those) were derived from GWA
data. We used the recessive model in this replication analysis.
Results
As expected, ND and MDD were significantly associated:
individuals with MDD diagnosis having higher likelihood for
lifetime ND (adjusted OR = 2.63, 95%CI 1.94–3.58, p = 3.0e-10)
and individuals with ND diagnosis having higher likelihood for
lifetime MDD (adjusted OR = 2.51, 95%CI 1.83–3.46, p = 7.6e-
09).
The bivariate quantitative twin model on MDD and ND
symptoms indicated substantial, although non-significant, correla-
tion between genetic components (rA = 0.51, 95% CI 20.11,
+1.00), whereas the correlation between environmental compo-
nents was moderate (rE = 0.21, 95% CI 0.09, +0.32). Albeit wide
confidence intervals, these results suggested that a substantial
proportion of the correlation between ND and MDD may derive
from shared genetic factors, justifying further analyses of specific
genes. The univariate moderation models indicated that ND
symptoms did not significantly moderate additive genetic
(x2(1) = 2.05, p = 0.15) or common environmental (x2(1),0.01,
p.0.99) variance of MDD. Instead, moderating on unique
environmental variance was detected (x2(1) = 14.0, p,0.001), such
that this variance (including error variance) of MDD symptoms
increased 5.3-fold in the absence of ND. No significant moder-
ation by MDD symptoms for genetic or environmental variance of
ND appeared (x2(3) = 0.36, p = 0.95).
The LD blocks for the SNPs were similar to those in the
HapMap CEPH data (Figure S1 in File S1) and the somewhat
stronger intermarker LD is in agreement with previous findings
from the Finnish population [42]. We detected a significant
association between DRD3 rs2399496 and the co-morbid pheno-
type of MDD and ND (p = 0.000079). Rs2399496 also showed
suggestive association with MDD (p = 0.00076) and a similar trend
with MDD symptoms (p = 0.0017). No significant or suggestive
association for ND diagnosis or symptoms appeared. We detected
no significant or suggestive association with SNPs in the other
genes (Table S3 in File S1). Association results for DRD3 SNPs are
presented in Table 2.
To follow up the marker exhibiting significant association for
MDD-ND co-morbidity (rs2399496 in DRD3), we divided
individuals with rs2399496 genotype available (N = 1353) into
those fulfilling (N = 692) and not fulfilling (N = 661) the DSM-IV
ND criteria. In separate association analyses for MDD, the
association signal emerged solely from nicotine dependent subjects
(data not shown). Similarly, we divided individuals into those
fulfilling (N = 239) and not fulfilling (N = 1114) the MDD criteria
and separately performed association analyses for ND, both
subgroups giving negative results (data not shown).
We could not replicate the association between rs2399496 and
depression or the co-morbid phenotype in the adolescent sample
(FT12), in the Finnish population sample (Health2000) or in the
Australian twin family sample (NAG-OZALC; rs9817063 used as
proxy for rs2399496, intermarker r2 = 0.8–0.9, depending on the
reference sample). Best evidence for replication was seen in the
NTR-NESDA sample for rs3732790 which is in high LD with
rs2399496 (r2 = 0.67, D’ = 0.997). No significant association with
MDD was seen in the whole NTR-NESDA sample (OR = 1.13,
95%CI 0.93, 1.36, p = 0.21) or among ever smokers (OR = 1.19,
95%CI 0.94, 1.52, p = 0.15). However, when analyzing the co-
morbid phenotype of MDD and ND the association became
stronger and significant (OR = 1.56, 95% CI 1.05, 2.33, p = 0.03).
Consistently with the study sample, no statistically significant
association was seen between rs3732790 and ND (OR = 1.17,
95%CI 0.88, 1.55, p = 0.28). Association results for all replication
samples are presented in detail in Tables S4a, S4b, S4c, and S4d
in File S1.
Finally, two hypotheses were tested in the study sample, i.e.
whether MDD potentiates the association of the SNP (rs2399496)
with ND or vice versa. When the SNP’s association with ND was
adjusted for MDD, sex, age, and alcohol use individuals carrying
one (TA) or two (AA) minor alleles did not have significantly
elevated risk for lifetime ND when compared to individuals
homozygous for the major allele (TT). Thus, the first hypothesis
was rejected. When the SNP’s association with MDD was adjusted
for ND, sex, age, and alcohol use, individuals carrying two minor
alleles (AA) had a nearly 2-fold risk for lifetime MDD (OR 1.89,
95% CI 1.26–2.84, p = 0.002) compared to individuals homozy-
gous for the major allele (TT) (Table 3). Although the interaction
test using the Nested Likelihood-ratio approach showed only a
trend towards SNP (rs2399496)-by-ND-interaction (LR
x2(2) = 5.13, p = 0.08) the p-value was ,0.10 – a cut point often
used to perform additional analyses. Thus, the analyses separately
by ND status were justified. Among nicotine dependent subjects
(N = 678), the corresponding genetic risk for MDD was 2.29-fold
(95% CI 1.37–3.83, p = 0.002), while no association was seen
among non-dependent subjects (N = 618) (Table 4).
To illustrate the relative contribution of the SNP and ND, we
created a new variable combining ND status and number of
rs2399496 minor alleles on individual level. Subjects with two
rs2399496 minor alleles (AA) and ND (N = 165) had more than
five-fold risk for lifetime MDD (OR 5.74, 95%CI 3.1–11, p = 9.0e-
09) compared to subjects not fulfilling ND criteria and carrying no
rs2399496 minor alleles (TT) (N = 177) (Table 5). We estimated
the proportion of co-variation of ND and MDD accounted for by
DRD3 rs2399496. Based on logistic regression where MDD co-
morbid with ND was the outcome variable rs2399496 explained
1.32% (Pseudo R2 = 0.0132) of co-variation. Finally, in order to
verify that the ND diagnosis in our data reflects chronic exposure
to cigarettes we conducted subgroup models, and detected
significant association between rs2399496 and MDD among 673
heavy (ever) smokers (smoked $20 CPD) (ORminor/minor = 2.44,
95% CI 1.45–4.10, p = 0.001). No association was detected among
575 non-heavy ever smokers.
Discussion
Utilizing a Finnish sample of twins and their siblings ascertained
for heavy smoking from the population based Finnish twin cohort,
we aimed to scrutinize the association between lifetime DSM-IV
diagnoses of MDD and ND, as well as the magnitude of genetic
factors associated with this co-morbidity. Ever smokers with ND
had over 2-fold risk for MDD compared to non-dependent ones,
in concordance with earlier literature [2]. We detected significant
association between rs2399496 1.5 kb downstream of DRD3 and
co-morbid MDD and ND. Rs2399496 is in high LD with
rs3732790 (D’ = 1.0, r2 = 0.55), 274 bp downstream of DRD3, and
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with intronic rs2134655 (D’ = 0.98, r2 = 0.46). Rs3732790 showed
similar trend, approaching suggestive association. As none of the
variants have a clear functional role, we hypothesize that the
detected association reflects LD with an unidentified functional
variant. Although rs2399496 is imputed in the GWA data, its high
minor allele frequency (0.47), results in improved imputation
accuracy compared to rare variants. Individuals carrying two
minor alleles had nearly 2-fold risk for lifetime MDD compared to
individuals homozygous for the major allele. Although no
association was detected between rs2399496 and ND, individuals
with two minor alleles and ND diagnosis had over five-fold risk for
lifetime MDD compared to individuals not fulfilling DSM-IV ND
criteria and carrying no minor alleles.
Our results do not substantiate pleiotropic associations of DRD3,
but rather support the gene-by-ND-interaction hypothesis, with
ND enhancing the influence of rs2399496 on MDD risk. As
portrayed in our second hypothesis, chronic heavy exposure to
nicotine, sustained by ND, can be deemed as an environmental
factor in the etiology of MDD. Supporting this, subgroup models
among individuals with ND diagnosis yielded similar results than
those among heavy ever smokers. Thus, in our data ND diagnosis
seemed to reflect chronic nicotine exposure, although the DSM-IV
ND criteria focus on other aspects of ND than smoking quantity.
Gene-by-environment-interaction has been previously reported for
DRD2 and DRD4 [17,18]. In discordance with previous reports,
we detected no association between the tested traits and DRD2
rs1800497 (TaqIA) or any of the other DRD2 SNPs. Similarly, no
Table 2. Association analyses results (p-values) for DRD3 SNPs.
Marker Gene DSM-IV MDD
DSM-IV MDD
symptoms DSM-IV ND
DSM-IV ND
symptoms
Co-morbidity of DSM-IV MDD
and ND
rs2399496 DRD3 0.00076 b 0.0017 0.058 1.000 0.000079 a
rs3732790 DRD3 0.0087 0.0072 0.482 0.286 0.011
rs2134655 DRD3 0.125 0.037 0.696 0.483 0.047
rs9880168 DRD3 0.072 0.337 0.996 0.584 0.194
rs324036 DRD3 0.098 0.337 1.000 1.000 0.089
rs324035 DRD3 0.759 0.732 0.533 0.695 0.910
rs167771 DRD3 0.998 0.609 0.985 0.901 0.648
rs11721264 DRD3 0.869 0.529 0.330 0.464 0.828
rs226082 DRD3 0.674 0.465 0.445 0.460 0.950
rs324029 DRD3 0.720 0.381 0.383 0.437 0.874
rs16822416 DRD3 0.304 0.876 0.740 0.674 0.115
rs9825563 DRD3 0.128 0.311 0.998 0.629 0.209
rs7629232 DRD3 0.207 0.289 0.423 0.915 0.333
rs6787134 DRD3 0.947 0.938 0.944 0.678 0.952
rs1354348 DRD3 0.292 0.678 0.592 0.035 0.556
DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition (APA 1994); MDD, major depressive disorder; ND, nicotine dependence.
a, significant p-value (study-specific threshold p,0.00042).
b, suggestive p-value (study-specific threshold 0.00042,p,0.0014).
doi:10.1371/journal.pone.0098199.t002
Table 3. Logistic regressions on the associations of lifetime DSM-IV nicotine dependence (ND)a and the DRD3 variant rs2399496
with lifetime DSM-IV major depressive disorder (MDD) b (N = 1296).
Outcome Model 1c Model 2
MDD Independent association of ND and gene Associations of ND and gene adjusted for each otherc
Risk Factor OR 95% CI p-value OR 95% CI p-value
ND
No 1.00 1.00
Yes 2.51 1.83–3.46 7.569e–09 2.48 1.80–3.41 1.512e–08
rs2399496
TT 1.00 1.00
TA 1.32 0.92–1.88 0.130 1.28 0.89–1.83 0.185
AA 1.97 1.30–2.96 0.001 1.89 1.26–2.84 0.002
aDSM-IV nicotine dependence diagnosis.
bDSM-IV major depression disorder diagnosis.
cAdjusted for sex, age, and alcohol abuse.
doi:10.1371/journal.pone.0098199.t003
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association was detected between DRD4 variants and the included
traits; however, the most commonly implicated DRD4 48-base-
pair-repeat polymorphism was not assessed in the current study.
We have the DRD4 48-bp minisatellite genotype data available in
a subset of the study sample (N = 651); no association was detected
with any of the phenotypes (data not shown).
Best evidence for replication was seen in the Dutch NTR-
NESDA sample with the MDD-ND co-morbid phenotype, with a
SNP in high LD with the SNP showing significant association in
the study sample. The detected association in the Dutch sample
may tag either the same or different underlying functional variant
than in the Finnish sample. It is highly plausible that the
underlying LD structure varies between the Finnish and Dutch
populations, especially when considering the unique genetic
architecture of Finns [42]. Population-specific functional variants
are known to exist, and one has already been documented in the
Finnish population for a behavioral trait [43]. Future studies are
needed to expose whether rs2399496 in the Finnish study sample
and rs3732790 in the Dutch NTR-NESDA sample tag the same
functional variant. In concordance with the results obtained from
Table 4. Logistic regressions on the associations of the DRD3 variant rs2399496 with DSM-IV major depressive disorder (MDD)
among sub-groups based on DSM-IV nicotine dependence (ND) statusa.
Outcome Non-nicotine dependent Nicotine dependent
MDD (N=618) (N=678)
Risk Factor OR 95% CI p-value OR 95% CI p-value
rs2399496
TT 1.00 1.00
TA 1.47 0.80–2.70 0.214 1.19 0.76–1.88 0.450
AA 1.23 0.58–2.60 0.583 2.29 1.37–3.83 0.002
aAdjusted for sex, age and alcohol abuse.
doi:10.1371/journal.pone.0098199.t004
Table 5. Logistic regressions on the associations of the DRD3 variant rs2399496 and nicotine dependence (ND) with major
depressive disorder (MDD): Models combining the ND (no/yes) and rs2399496 (TT = 0, TA = 1, or AA= 2 minor alleles) status.
Adjusted model a
(N=1296)
OR 95% CI p-value
‘Effects’ of increasing number of risk factors
no ND + TT 1.00
no ND + TA 1.48 0.80–2.75 0.214
no ND + AA 1.24 0.58–2.64 0.581
ND + TT 2.50 1.30–4.83 0.006
ND + TA 3.01 1.72–5.28 0.00006
ND + AA 5.74 3.12–10.5 9.010e-09
‘Effect’ of nicotine dependence
no ND + TT 1.00
no ND + TA 0.81 0.38–1.72 0.581
no ND + AA 1.19 0.63–2.28 0.589
ND + TT 2.01 1.04–3.93 0.038
ND + TA 2.43 1.30–4.56 0.006
ND + AA 4.63 2.42–8.88 3.561e-06
‘Effect’ of the number of minor gene alleles
ND + TT 1.00
no ND + TT 0.40 0.21–0.77 0.006
no ND + TA 0.59 0.35–1.00 0.051
no ND + AA 0.49 0.25–0.96 0.038
ND + TA 1.20 0.77–1.89 0.421
ND + AA 2.29 1.38–3.82 0.001
aAdjusted for sex, age, and alcohol abuse.
doi:10.1371/journal.pone.0098199.t005
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the study sample, no statistically significant direct association was
seen with ND in the NTR-NESDA sample. The association did
not replicate in the Finnish adolescent FT12 sample or adult
population sample or in the Australian twin family sample (NAG-
AUS). In the adolescent sample DSM-IV ND diagnosis was not
available, so FTND was used instead. DSM-IV predominantly
measures loss of control in smoking behavior [44] while FTND
measures physical dependence [45]. Concerning MDD, the FT12
sample was interviewed at an average age of 21.9 (SD 0.8, range
21–26). Prevalence of lifetime MDD was 12%, comparable to
studies reporting 15–20% of youth experiencing a MDD episode
by age 20 [1]. However, the core phenotype in genetic analyses
was co-morbidity of MDD and ND with prevalence of only 2.8%
(N = 38) in the FT12 sample. Thus, those analyses suffered from
lack of power. In the population-based Health2000 sample MDD
and ND DSM-IV diagnoses were not available; rather, we
investigated associations with depression phenotypes defined by
the CIDI for major depressive episode [23], and the BDI, a 21-
question multiple-choice self-report inventory measuring severity
of depression. In an attempt to create a phenotype resembling co-
morbid MDD and ND, we examined depression phenotypes
among heavy ($20 CPD) ever smokers. The lack of association
may partly reflect inappropriate phenotype definitions, as we had
no means to identify the ‘extreme’ individuals with DSM-IV
diagnoses for both MDD and ND. Lack of association in the
Australian sample, despite availability of identical phenotypes,
may reflect population specificity of the detected risk variant.
Our results expand the existing knowledge on the etiology of
MDD and ND. It is plausible that the scarcity of association
findings for DRD3 and for the other dopamine receptor genes is partly
due to complexity of the underlying mechanisms and inability to
capture the signal when investigating one phenotype at a time. To
date, single studies have identified specific DRD3 variants
associating with FTND defined ND [46], heaviness of smoking
index, and time to first cigarette in the morning [11], as well as
treatment response and remission in depression patients [47].
Converging pharmacological, post-mortem, and genetic data
have suggested involvement of DRD3 in drug dependence. Rather
than being involved in direct reinforcing effects of drugs of abuse,
DRD3 appears to be implicated in motivation to self-administer
drugs under schedules where response requirements are high [48].
A 30% reduction of DRD3 expression in peripheral blood
lymphocytes has been reported in current smokers compared to
controls with no lifetime regular smoking, DRD3 expression
correlating negatively with CPD [49]. Given the known involve-
ment of DRD3 in reward mediation, such selective inhibiting effect
of smoking on DRD3 expression indicates vicious-cycle explana-
tion of motivation for continued smoking [49]. Dysfunction of
dopamine D3 receptors has also been linked to the pathogenesis of
major depression [3]. Preclinical data show enhanced D3 receptor
binding in the striatum upon antidepressant medication and
electroconvulsive therapy [47].
We diligently addressed multiple testing. As the included
markers and traits are correlated, standard procedures of
correcting for multiple testing would be overly conservative. Thus,
we used modified Bonferroni correction and utilized estimated
numbers of independent markers and traits to set p-value
thresholds for significant and suggestive associations. Estimation
of independent markers, based on LD matrixes, is straightforward;
however, estimating the number of independent traits is more
challenging. We used a statistical estimate based on the
correlation/covariance matrix, resulting in a sample-based
estimate that may vary in novel independent population samples.
Using estimated numbers of independent markers and traits in
adjusting p-value thresholds is still quite conservative but
nevertheless successful in reducing type I errors.
Although our sample size is moderate it is significantly larger
than in most previous candidate gene studies addressing dopamine
receptor genes and ND or depression. Our data on twins and
siblings were ascertained specifically for smoking, the initial sample
being drawn from the population-based Finnish twin cohort with
extensive phenotypic profiles. Due to enrichment for ND (52% in
the study sample vs. 40% in the Finnish population) our sample is
also enriched for commonly co-occurring depression (17–18% in
the study sample vs. 8–13% in the general population) yielding
more power than presumed based on sample size. With adequate
numbers of affected individuals available, we were able to focus on
the most extreme phenotypes, i.e. DSM-IV diagnoses of ND and
MDD, instead of investigating non-diagnostic phenotypes such as
CPD and number of depressive symptoms. Although considered
more powerful per se, neither of the quantitative DSM-IV
symptom counts proved more informative than the corresponding
dichotomous DSM-IV diagnoses. This is not surprising, as trait
distributions in our enriched sample do not correspond with the
population-level trait variance. Individuals with the most extreme
phenotypes are likely to possess the most predisposing genetic
variants [50] thus being most informative in genetic association
analyses. Furthermore, the Finnish population represents a well-
established isolate with minuscule population admixture. In
isolates, genetic drift may lead to overabundance of morbid alleles
for particular disorders and high proportion of patients is likely to
share these alleles IBD. Although the association is strongest for
rare disease alleles, isolates are also advantageous for genetic
studies of common disorders [51]. Further, we should note that it
is likely that our samples under study are relatively homogeneous
being from the Finnish population, with little risk of bias from
population stratification.
In this study where MDD-ND phenotype was the outcome
variable rs2399496 explained 1.32% of the variance. This level of
explanation is comparable to the finding of three genome-wide
association (GWA) studies which reported variation in 15q24-25,
containing three nAChR genes (CHRNA5, CHRNA3, CHRNB4),
contributing to lung cancer risk and associating strongly with
amount of smoking and ND [52–54] and where less than 1% of
the variance in number of daily cigarettes smoked was explained
by alleles of these genes.
To conclude, we detected a significant association between
DRD3 rs2399496 and MDD-ND co-morbid phenotype. We
further demonstrated that ND strengthens the influence of the
genetic variant on MDD, suggestive of gene-by-environment-
interaction. We could not provide significant replication for these
findings.
Supporting Information
File S1 Figure S1 and Tables S1–S4. Figure S1. A) DRD3
gene structure, B) genotyped SNPs, C) D’ in the HapMap CEPH
data (NCBI Build 36), D) r2 in the HapMap CEPH data, E) D’ in
the study sample (non-related individuals; one per family), F) r2 in
the study sample. Table S1. Correlations between the included
phenotypes. Correlations were computed by polychoric (tetra-
choric and point biserial) and spearman correlation. Number of
individuals varies from 1326 to 1428 depending on presence of
missing values. Table S2. Marker quality controls. Table S3.
Association analysis results (p-values) for all dopamine receptor genes.
The study-specific P-value threshold for significant and suggestive
association is 0.00042 and 0.0014, respectively. Table S4. a. The
association of rs2399496, rs3732790 and rs2134655 with nicotine
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dependence (ND) and Major Depressive Disorder (MDD) in the
Australian NAG-OZALC sample. Age, sex, and principal
components (for population stratification) were used as covariates.
All results are based on recessive models. b. The associations of
rs2399496, rs3732790 and rs2134655 with nicotine dependence
(ND) and Major Depressive Disorder (MDD) in the NTR-NESDA
sample. Age, sex, and principal components (for population
stratification) were used as covariates. All results are based on
recessive models. c. The associations of rs2399496, rs3732790 and
rs2134655 with nicotine dependence (ND) and Major Depressive
Disorder (MDD) in the FT12 sample. Age and sex were used as
covariates. All results are based on recessive models. d. The
associations of rs2399496, rs3732790 and rs2134655 with nicotine
dependence (ND1) and Major Depressive Disorder (MDD) in the
T2000 sample. Age and sex were used as covariates. All results are
based on recessive models.
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